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Evaluation of a low-dose desoxycorticosterone pivalate treatment 1 
protocol for long-term management of dogs with primary 2 
hypoadrenocorticism  3 
 4 
Abstract 5 
Background: Lowering the dose of desoxycorticosterone pivalate (DOCP) for the 6 
treatment of dogs with primary hypoadrenocorticism (PH) decreases costs and could 7 
lead to increased owner motivation to treat affected dogs.  8 
Objective: To evaluate the efficacy of a low-dose DOCP treatment protocol in dogs 9 
with PH. 10 
Animals: Prospective study, 17 client-owned dogs with naturally-occurring PH (12 11 
newly diagnosed, 5 previously treated with fludrocortisone acetate [FC]).  12 
Methods: Dogs with newly diagnosed PH were started on 1.5 mg/kg DOCP SC; 13 
dogs previously treated with FC were started on 1.0-1.8 mg/kg DOCP SC. 14 
Reevaluations took place at regular intervals for a minimum of 3 months and included 15 
clinical examination and determination of sodium and potassium concentrations. The 16 
DOCP dosage was adjusted to obtain an injection interval of 28-30 days and to keep 17 
serum electrolyte concentrations within the reference interval.  18 
Results: Median (range) follow-up was 16.2 months (4.5-32.3). The starting dosage 19 
was sufficient in all but 2 dogs and had to be significantly decreased after 2-3 months 20 
to a median dosage (range) of 1.1 mg/kg (0.7-1.8). Dogs £ 3 years of age needed 21 
significantly higher dosages compared to older dogs. None of them, however, 22 
needed the 2.2 mg/kg DOCP dosage, recommended by the manufacturer. 23 
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Conclusions and clinical relevance: A starting dosage of 1.5 mg/kg DOCP is 24 
effective in controlling clinical signs and electrolyte concentrations in the majority of 25 
dogs with PH. An additional dose reduction often is needed to maintain an injection 26 
interval of 28-30 days. Young and growing animals seem to need higher dosages.   27 
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Introduction 28 
Most dogs with primary hypoadrenocorticism (PH) suffer from immune-mediated 29 
destruction of the adrenocortex, which results in absolute glucocorticoid and 30 
mineralocorticoid deficiency. Treatment of PH consists of life-long replacement with 31 
both hormones. Mineralocorticoids usually are replaced by either PO fludrocortisone 32 
acetate (FC) or by SC injection of desoxycorticosterone pivalate (DOCP). The latter 33 
is a parenteral long-acting mineralocorticoid with no glucocorticoid activity. In 1998, 34 
the US Food and Drug Administration (FDA) approved DOCP (PercortenÒ-V, 35 
Novartis Animal health US, Greensboro, NC, USA) for mineralocorticoid replacement 36 
therapy in dogs with PH.1 An alternative DOCP product (ZycortalÒ, Dechra 37 
Pharmaceuticals, Overland Park, KS, USA) was approved in 2015 by the European 38 
Medicines Agency and in 2016 by the FDA.2,3 ZycortalÒ is produced by a different 39 
manufacturer than PercortenÒ-V and differs slightly from the latter with regard to the 40 
preservative (chlorocresol rather than thimerosal) and the surfactant (polysorbate-60 41 
rather than polysorbate-80). It is the only product licensed in Europe for the treatment 42 
of PH. In July 2018, because of a shortage of PercortenÒ-V, the FDA proposed 43 
ZycortalÒ as an alternative. In pharmacological studies, the effectiveness of ZycortalÒ 44 
was shown to be “non-inferior” to that of PercortenÒ-V and the same starting dosage 45 
of 2.2 mg/kg every 25 days was recommended by the manufacturer.  46 
Because the expense of DOCP can be a limiting factor for some owners, finding the 47 
lowest effective dose for each dog is important. In previous studies using the 48 
originally licensed DOCP (PercortenÒ-V), it was shown that in the majority of dogs 49 
the clinical disease can be well controlled with substantially lower dosages than the 50 
recommended 2.2 mg/kg.5-7 Another strategy to decrease treatment costs is 51 
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prolongation of the injection interval. 7 The duration of action of DOCP (PercortenÒ-V) 52 
has been shown to range from 32 to 94 days in dogs newly diagnosed with PH.7  53 
However, in no published study has a fixed starting dosage of DOCP been 54 
evaluated. Further, to our knowledge, no studies have evaluated whether, using the 55 
newly registered DOCP product (ZycortalÒ), lower doses than recommended by the 56 
manufacturer are effective in controlling clinical signs.  57 
Thus, the aims of our study were to evaluate a low-dose treatment protocol using the 58 
new DOCP product (ZycortalÒ) in dogs with naturally occurring PH and to identify the 59 
lowest possible dose needed to obtain a monthly injection interval of 28-30 days.   60 
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Material and Methods 61 
Animals 62 
Seventeen client-owned dogs with naturally occurring PH were prospectively enrolled 63 
between May 2016 and March 2018. Primary hypoadrenocorticism was diagnosed 64 
based on a post-ACTH serum cortisol concentration of < 1 µg/dl, abnormal serum 65 
sodium (Na) and potassium (K) concentrations, increased plasma endogenous 66 
ACTH concentrations or both. 67 
Ages ranged from 0.3 – 9 years (median, 3.8 years) and body weight from 3.2 - 74.2 68 
kg (median, 25.7 kg). There were 6 males (4 castrated) and 11 females (7 spayed). 69 
Eleven purebred dogs (Bearded Collie [1], Dachshund [1], German Shepherd dog 70 
[1], Golden Retriever [1], Great St Bernard [2], Labradoodle [1], Labrador Retriever 71 
[3], Miniature Poodle [1]) and 6 mixed-breed dogs were included. Presenting clinical 72 
signs included vomiting, diarrhea, anorexia or hyporexia, weight loss, weakness, 73 
lethargy, polyuria, polydipsia, or some combination of these. Blood urea nitrogen 74 
concentration was increased in 12/17 dogs. 75 
Analytical procedures 76 
For the ACTH stimulation test, blood samples were taken before and 60 min after IV 77 
injection of 5 µg/kg synthetic ACTH (SynacthenÒ, Future Health Pharma GmbH, 78 
Wetzikon, Switzerland). Serum cortisol concentrations were measured by a 79 
competitive immunoassay (DPC ImmuliteÒ 2000, Siemens Schweiz AG, Zurich, 80 
Switzerland), previously validated in dogs and performed according to the 81 
manufacturer’s instructions.8 As reported by the manufacturer, the sensitivity of the 82 
assay is 0.2 µg/dl and the intra-assay coefficients of variation were 10% and 6% at 83 
cortisol concentrations of 2.7 and 18.9 µg/dl, respectively. For the determination of 84 
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plasma endogenous ACTH, blood was collected before ACTH administration into 85 
chilled EDTA-coated tubes, placed on ice, and centrifuged at 4°C within 30 minutes. 86 
Plasma ACTH concentrations were determined using a 2-site solid-phase 87 
chemiluminescent immunometric assay (DPC ImmuliteÒ 2000, Siemens Schweiz AG, 88 
Zurich, Switzerland), previously validated for dogs.9,10 Cortisol and endogenous 89 
ACTH measurements were performed in house by a commercial laboratory twice a 90 
week; plasma was stored either at -20°C (cortisol) or at -80°C (ACTH) until assayed. 91 
Plasma Na and K concentrations were determined by a commercial laboratory using 92 
a Roche Hitachi 501 chemistry analyzer (Roche Pharma Schweiz AG, Reinach, 93 
Switzerland). 94 
Treatments 95 
In 12 dogs, PH was newly diagnosed at the time of inclusion in the study. 96 
Mineralocorticoid replacement treatment was started with DOCP (ZycortalÒ) after an 97 
individualized stabilization period that included among other treatments, IV fluids, 98 
management of hyperkalemia by glucose infusion, and prednisolone administration. 99 
The starting dosage of DOCP was 1.5 mg/kg SC and the target injection interval was 100 
q28-30 days. Efficacy of DOCP treatment was assessed on days 14 and 28 after the 101 
first injection by monitoring clinical signs and serum K and Na concentrations. 102 
Depending on serum K and Na concentrations 14 and 28 days after injection, DOCP 103 
dosage was adjusted and the injection interval changed to arrive at serum K and Na 104 
concentrations within the reference interval. If the serum K concentration was below 105 
the reference interval (4.3-5.3 mmol/L) and the serum Na concentration was within 106 
the reference interval (145-152 mmol/L) 14 days after DOCP injection, the dosage 107 
was reduced by 5-10% at the next injection. If the serum K concentration was < 4.3 108 
mmol/L 28 days after injection, the next injection was postponed and serum 109 
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electrolyte concentrations evaluated at a weekly interval. As soon as serum K 110 
concentration was within the reference interval, the next DOCP dose was 111 
administered at decreased dosage (5-10% reduction for every week of delayed 112 
injection). With this approach, we aimed for an injection interval of 28-30 days and a 113 
target dose of DOCP at which serum Na and K concentrations remained within the 114 
reference interval.  115 
Five dogs previously had been diagnosed with PH and PO FC (FlorinefÒ, Bristol-116 
Myers Squibb SA, Baar, Switzerland) treatment had been started 1 to 18 months 117 
(median, 6 months) before inclusion in the study. At the time of inclusion, 118 
mineralocorticoid treatment was changed from PO FC to SC DOCP. The starting 119 
dosage of DOCP was 1.8 mg/kg in 1 dog, 1.5 mg/kg in 1 dog, 1.2 mg/kg in 2 dogs 120 
and 1 mg/kg in 1 dog. The DOCP dosage for these dogs was determined, among 121 
other things, on actual serum electrolyte concentrations and owner financial 122 
concerns, and was adjusted as described above.  123 
All dogs were treated with prednisolone and starting dosages in the dogs with newly 124 
diagnosed PH ranged between 0.5 and 1 mg/kg IV q6 to q12 h for a duration of 12–125 
48 h, depending on the severity of clinical signs and the condition of the dog. 126 
Prednisolone treatment was changed to PO as soon as the dogs ate and vomiting 127 
stopped. At the time of discharge, the prednisolone dosage was decreased to 0.5 128 
mg/kg PO q24h and further reduction was individualized based on clinical signs (e.g., 129 
appetite, activity level, diarrhea, vomiting, polyuria, polydipsia, weight gain) and on 130 
assessment by the clinician. In general, the goal was to reach a glucocorticoid 131 
dosage £0.1 mg/kg PO q24h with no signs of glucocorticoid excess (e.g., polyuria, 132 
polydipsia, polyphagia, muscle loss).  133 
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In dogs previously treated with PO FC, the starting dosage of prednisolone was 0.1 134 
mg/kg per day.  135 
Study design 136 
A minimum follow-up period of >3 months was necessary to be included in the study. 137 
The DOCP dosage and serum Na and K concentration were recorded at the time of 138 
inclusion and after 1-2, 2-3, 3-6, 6-12, 12-18, 18-24 and > 24 months during follow-139 
up. All variables were recorded on the day of the DOCP injection.  140 
All procedures were conducted in accordance with guidelines established by the 141 
Animal Welfare Act of Switzerland. In addition, informed consent of the pet owners 142 
was obtained before including dogs in the study.  143 
Statistical analysis 144 
Statistical analysis was performed by means of non-parametric tests using 145 
commercial software (SPSS, Statistical Package for the Social Science, Software 146 
Packets for Windows, Version 23; GraphPad Prism6, GraphPad Software, San 147 
Diego, CA, USA). Data are expressed as median and range. Changes in DOCP 148 
dosage and changes in serum K and Na concentrations during therapy were 149 
evaluated by Friedman’s repeated measures test and Dunn’s post-test. ZycortalÒ 150 
dosages between age groups and between dogs previously treated with FC and 151 
those initially treated with DOCP were tested by Mann-Whitney U test. The level of 152 
significance was set at p < 0.05.  153 
  154 
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Results 155 
DOCP dosage 156 
Median (range) follow-up period on DOCP treatment of all 17 dogs was 16.2 months 157 
(4.5-32.3); all except 1 dog were still alive at the end of the study period. This 1 dog 158 
had to be euthanized after 28.5 months of DOCP treatment because of gastric 159 
dilatation and -volvulus. All except 1 dog were still on DOCP treatment at the end of 160 
the observation period; 1 dog had to be changed to PO FC after 15.4 months of 161 
DOCP treatment, despite excellent clinical control, because the owner was no longer 162 
able to give the injections.  163 
For all dogs, results at inclusion and after 1-2, 2-3 and 3-6 months were available. 164 
After 6-12, 12-18, 18-24 and > 24 months, results of 14, 13, 6 and 4 dogs, 165 
respectively, could be included. Overall, a significant decrease in the DOCP dosage 166 
was observed during the study (p=0.026; Table 1; Figure 1).  167 
At the first reevaluation, the DOCP dose was decreased and the injection interval 168 
increased because of hypokalemia in 15 dogs. At the second reevaluation, the 169 
DOCP dose was decreased in 7 dogs, and in 5 of the 7 dogs, the injection interval 170 
was increased. Injection intervals for the first 3 months of treatment of all dogs are 171 
presented in Table 2. In 2 dogs, the DOCP dose first had to be increased and later 172 
during the follow-up period decreased again. One of the 2 dogs was a 4-month-old 173 
Dachshund. In this dog, the DOCP dosage was increased 2.4 months after inclusion 174 
from 1.5 to 1.7 mg/kg. Nine months after inclusion (at the age of 13 months), 175 
however, the DOCP dosage had to be decreased to 1.5 mg/kg again and 2 months 176 
later to 1.0 mg/kg. The second dog was a 3-year-old Great St Bernard, which, 177 
because of financial concerns, first had been treated with PO FC. The FC dose had 178 
to be continually increased because of serum electrolyte concentrations outside of 179 
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the reference interval. After 6 months, treatment was finally changed to DOCP 180 
because of glucocorticoid-associated adverse effects (polyuria, polydipsia, muscle 181 
loss) despite discontinuation of prednisolone. The dog was started on a DOCP 182 
dosage of 1.2 mg/kg, but the dosage had to be increased to 1.3 mg/kg and 1.6 mg/kg 183 
after 1.7 and 2.7 months, respectively. After 4.3 months, the DOCP dosage was 184 
steadily decreased to a final dosage of 0.7 mg/kg, which was reached after 28.5 185 
months of therapy.  186 
In dogs with £ 3 years of age (7 dogs), the DOCP dose 3 months after starting 187 
therapy was significantly higher compared to dogs > 3 years of age (10 dogs; 188 
p=0.03).  189 
No significant difference in ZycortalÒ dosage was found between dogs previously 190 
treated with FC and those that were immediately started on ZycortalÒ.  191 
 192 
Serum K concentrations 193 
Serum K concentrations decreased during DOCP therapy. The decrease compared 194 
over all reevaluations, however, was not statistically significant (Friedman test, 195 
p=0.809). Results (median, range) at the different time points during reevaluation are 196 
presented in Table 1 and Figure 2. 197 
 198 
Serum Na concentration 199 
Serum Na concentrations increased during DOCP therapy. The increase compared 200 
over all reevaluations, however, was not statistically significant (Friedman test, 201 
p=0.154). Results (median, range) at the different time points during reevaluation are 202 
presented in Table 1 and Figure 3. Selected dogs had mild hyponatremia at different 203 
time points during treatment despite their serum K concentrations being within the 204 
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reference interval. Mild hypernatremia was observed in 1 dog 3 months after starting 205 
treatment.  206 
  207 
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Discussion 208 
We were able to show that all dogs with PH, started on a lower DOCP dosage than 209 
recommended by the manufacturer, could be effectively treated and stabilized.  210 
Pharmacological studies by the manufacturer had shown that DOCP (ZycortalÒ) 211 
administered at the dosage of 2.2 mg/kg was well tolerated in purpose-breed beagle 212 
dogs. Even dose increases up to as much as 5-fold the labeled dosage for 6 months 213 
seemed not harmful.2,3 At first consideration, there may be no indication to 214 
recommend a lower starting dose except cost reduction. However, our data show 215 
that even with a lower starting dosage of 1.5 mg/kg, hypokalemia seems to be a 216 
common observation 28 days after the first injection, necessitating not only dose 217 
reduction but also prolongation of the injection interval. Clearly, hypokalemia is far 218 
less dangerous than the hyperkalemia of untreated dogs with PH, but, clinical signs 219 
such as weakness still might be observed in dogs with hypokalemia associated with 220 
inappropriately high doses of DOCP. Moreover, another aspect of treatment 221 
monitoring must be taken into consideration. Dose adjustment of DOCP in our study, 222 
but also in previous studies, was only based on clinical signs and serum Na and K 223 
concentrations. Determination of plasma renin activity (PRA) is the most sensitive 224 
marker in human medicine for identifying insufficient as well as excessive 225 
mineralocorticoid replacement.11 In a previous study, we found completely 226 
suppressed (i.e., below the detection limit of the assay) PRA concentrations in dogs 227 
with PH treated with the original DOCP product (PercortenÒ-V).12 In human medicine, 228 
this is a clear indication of excessive treatment with mineralocorticoids and can 229 
indicate a risk for iatrogenic hypertension and potential long-term complications in 230 
these patients.11 Short-term treatment of dogs with 2.2 mg/kg DOCP (PercortenÒ-V) 231 
did not lead to hypertension, but long-term studies including determination of PRA as 232 
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a monitoring tool and measurement of blood pressure during therapy have not yet 233 
been performed in dogs.13 Therefore, in our study, despite serum Na and K 234 
concentrations within the reference interval, dogs still could have been exposed to 235 
inappropriately high doses of DOCP. Hence, veterinarians should strive to find the 236 
lowest possible dose of DOCP, not only to achieve lower treatment costs, but also for 237 
safety reasons to avoid possible, as yet undescribed, adverse effects of long-term 238 
overtreatment.  239 
Despite decreases in serum K concentrations below the reference interval, 240 
development of severe hypernatremia has not been described, neither in our study 241 
(only 1 dog with mildly increased serum Na concentration 3 months after starting 242 
therapy) nor in previous studies using the original DOCP product (PercortenÒ-V). 243 
This is not surprising, because in healthy Beagle dogs receiving up to 5-times the 244 
labeled dosage of ZycortalÒ either normonatremia or only mild hypernatremia was 245 
observed.2 Mineralocorticoid excess is known to lead to “aldosterone escape”, 246 
characterized by increased renal perfusion and natriuresis, which prevents non-247 
physiologically high increases in serum Na concentration.14,15 248 
A DOCP dose increase was necessary in only 2 dogs. One dog was a puppy in 249 
which the dosage had to be increased to 1.7 mg/kg. Interestingly, at the ages of 13 250 
and 15 months (the time when this study was written), the dosage could be 251 
decreased to 1.5 and 1 mg/kg, respectively. We assume that this change 252 
corresponded with the end of the dog’s growth period. Also, in another study, the 253 
DOCP dose had to be increased in a 4-month old dog, which was attributed to the 254 
dog’s continued growth.6 However, it also could be a sign of young age independent 255 
of growth, meaning that at older ages, lower dosages are needed. In fact, we were 256 
able to show a significant difference in the DOCP dose when comparing younger to 257 
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older dogs. This phenomenon also has been observed in another study using the 258 
original DOCP product (i.e., a higher dosage was needed in younger than in older 259 
dogs).7 Interestingly, registration and approval documents of the manufacturer show 260 
that their healthy research Beagle dogs were between 5-6 months of age.1,3 This 261 
seems a likely explanation for the manufacturer’s recommendation of a relatively high 262 
2.2 mg/kg starting dosage.  263 
In a double-blinded 180-day field study by the manufacturer, ZycortalÒ was found to 264 
be “non-inferior” to PercortenÒ-V, and a mean injection interval of 38.5 ±12.5 days 265 
with a range of 20-99 days was observed.2 Also in a study using PercortenÒ-V in 266 
dogs newly diagnosed with PH, the investigators were able to show that serum K and 267 
Na concentrations could be maintained within the reference interval for a median 268 
duration of 62 days, with a range of 32-94 days, using a dosage of 2.2 mg/kg.7 Based 269 
on these results, the injection interval using a high starting dosage, may be highly 270 
variable with both products and may be as long as 99 days. For owners, however, 271 
considerable variation in the injection interval might lead to poor compliance, which 272 
could be dangerous or life-threatening for the dog. A treatment interval of 28-30 days 273 
corresponds to 1 injection per month, which is easier for owners to remember and 274 
likely would result in improved compliance. However, even with our low-dose starting 275 
protocol, major variations in the injection interval were observed within the first 3 276 
months, necessitating a dose reduction in all but 2 dogs.  277 
All owners were satisfied with the treatment response using DOCP, including those 278 
whose dogs were changed from PO FC to SC DOCP because of adverse 279 
glucocorticoid effects or lack of normalization of serum electrolyte concentrations. No 280 
difference was observed in the DOCP dosage in dogs previously treated with FC 281 
compared to newly diagnosed dogs treated with DOCP. In addition, DOCP treatment 282 
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was superior to the prior FC treatment in terms of owner satisfaction, improvement of 283 
clinical signs, fewer or no adverse effects and improved control of serum Na 284 
concentrations. This observation also was made in earlier studies using PercortenÒ-285 
V.5,12  286 
Potential limitations of our study are the low number of dogs and the lack of PRA 287 
determination as a monitoring tool, as discussed above. Considering the case 288 
number, we can say that, although low, in none of the dogs was the high dosage of 289 
2.2 mg/kg needed. Moreover, a significantly lower dosage than our already low 290 
starting dosage of 1.5 mg/kg was needed, with decreases to dosages as low as 0.35 291 
mg/kg. Therefore, the 2.2 mg/kg dosage recommended by the manufacturer seems 292 
too high to maintain dogs at a targeted injection interval of 28-30 days.  293 
In conclusion, DOCP dosage is highly variable and should be titrated to the needs of 294 
each individual animal. A starting dosage of 1.5 mg/kg seems adequate in the 295 
majority of dogs. In all but 2 dogs, decreasing doses were necessary to obtain an 296 
injection interval of 28-30 days and to avoid overdosing as assessed by serum 297 
electrolyte concentrations outside of the reference interval. Dosages higher than 1.5 298 
mg/kg may be needed in young growing dogs. Further studies are needed, to confirm 299 
this suspicion.  300 
  301 
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Figure legends:  344 
Figure 1: DOCP dosage (mg/kg body weight) at the time of first injection (0) and at  345 
selected time points during the follow-up period of each dog. 346 
 347 
Figure 2: Serum Na concentrations (mmol/L) at the time point of diagnosis (D), on 348 
the day of DOCP injection (0) and at selected time points during the follow-up period 349 
of each dog. The area between the dotted lines represents the reference range of the 350 
serum Na concentration.  351 
 352 
Figure 3: Serum K concentrations (mmol/L) at the time point of diagnosis (D), on the 353 
day of DOCP injection (0) and at selected time points during the follow-up period of 354 
each dog. The area between the dotted lines represents the reference range of the 355 
serum K concentration.356 
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Tables 357 
Table 1 358 
Dosage of DOCP, serum potassium (mmol/L) and serum sodium concentrations (mmol/L) (median and range) at different time 359 
points. (Reference interval of sodium: 145-152 mmol/L; potassium: 4.3-5.3 mmol/L) 360 
 Diagnosis Start 
DOCP 
1-2 mo 2-3 mo 3-6 mo 6-12 mo 12-18 mo 18-24 mo > 24 mo 
Dosage DOCP NA 1.5a  
(1-1.8) 
1.2a,c 
(0.9-1.8) 
1.1a 
(0.7-1.8) 
1  
(0.6-1.7) 
0.8  
(0.6-1.7) 
0.8b,c 
(0.4-1.5) 
0.7b,c  
(0.35-0.75) 
0.7b,c 
(0.35-0.75) 
Potassium 
concentration 
7.6  
(4.1-8.9) 
5.2  
(4.3-6.6) 
4.7  
(4.1-5.7) 
4.5  
(4.1-6.5) 
4.6  
(3.9-5) 
4.5  
(4.2-4.9) 
4.7  
(3.5-5.3) 
4.4  
(4.3-4.8) 
4.2  
(4.1-4.2) 
Sodium 
concentration 
131  
(111-139) 
141  
(130-147) 
147  
(139-149) 
146  
(131-152) 
148  
(140-153) 
147  
(143-150) 
147  
(142-152) 
147  
(143-148) 
149 
DOCP: desoxycorticosterone pivalate; mo: months;  361 
Within a row different superscript letters indicate statistical differences between the time points (p<0.05) 362 
 363 
 364 
 365 
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Table 2 366 
Injection intervals after starting DOCP therapy given in days counted from the last 367 
injection up to the next following injection.  368 
 
Days after 1st 
injection 
Days after 2nd 
injection 
Days after 3rd 
injection 
Median 33 29 30 
Minimum 27 25 27 
Maximum 49 71 40 
 369 
